Risk of second primary malignancies following cutaneous melanoma diagnosis: A population-based study

Journal of the American Academy of Dermatology

Volumn 62, Issue 5, 2010, Pages 757-767

  Spanogle, Joshua P ^a   Clarke, Christina A ^b,c   Aroner, Sarah ^b   Swetter, Susan M ^a,c,d  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHERN CALIFORNIA CANCER CENTER   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

cutaneous melanoma; melanoma; melanoma survivorship; second primary malignancy; Surveillance, Epidemiology, and End Results program

Indexed keywords

ADULT; AGED; ARTICLE; BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVOR; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EYE CANCER; FEMALE; HUMAN; JOINT CANCER; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORBIDITY; NONHODGKIN LYMPHOMA; ORBIT CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; SALIVARY GLAND CANCER; SECOND CANCER; SOFT TISSUE CANCER; THYROID CANCER;

AGED; BONE NEOPLASMS; CALIFORNIA; FEMALE; HUMANS; INCIDENCE; JOINT DISEASES; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROSTATIC NEOPLASMS; REGISTRIES; RISK; SALIVARY GLAND NEOPLASMS; SEER PROGRAM; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; UNITED STATES;

EID: 77950595817     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.07.039     Document Type: Article

References (52)

1. Geller A.C., Swetter S.M., Brooks K., Demierre M.F., and Yaroch A.L. Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 57 (2007) 555-572
2. American Cancer Society. Cancer facts and figures 2007. Available from: URL:http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp. Accessed April 14, 2008.
3. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al, editors. SEER cancer statistics review, 1975-2005. National Cancer Institute. Available from: URL:http://seer.cancer.gov/csr/1975_2005. Accessed May 15, 2008.
4. Tucker M.A., Boice J.D., and Hoffman D.A. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-1982. Natl Cancer Inst Monogr 68 (1985) 161-189
5. DiFronzo L.A., Wanek L.A., Elashoff R., and Morton D.L. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol 6 (1999) 705-711
6. Schmid-Wendtner M.H., Baumert J., Wendtner C.M., Plewig G., and Volkenandt M. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 145 (2001) 981-985
7. Frank W., and Rogers G.S. Melanoma update: second primary melanoma. J Dermatol Surg Oncol 19 (1993) 427-430
8. Levi F., La Vecchia C., Randimbison L., Te V.C., and Erler G. Incidence of invasive cancers following cutaneous malignant melanoma. Int J Cancer 72 (1997) 776-779
9. Wolff J., and Wollina U. Second malignancies in melanoma patients in Thuringia. J Eur Acad Dermatol Venereol 14 (2000) 479-483
10. Goggins W.B., Finkelstein D.M., and Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer 91 (2001) 874-880
11. Riou J.P., Ariyan S., Brandow K.R., and Fielding L.P. The association between melanoma, lymphoma, and other primary neoplasms. Arch Surg 130 (1995) 1056-1061
12. Gutman M., Cnaan A., Inbar M., Shafir R., Chaitchik S., Rozin R.R., et al. Are malignant melanoma patients at higher risk for a second cancer?. Cancer 68 (1991) 660-665
13. Schallreuter K.U., Levenig C., and Berger J. Cutaneous malignant melanomas with other coexisting neoplasms: a true association?. Dermatology 186 (1993) 12-17
14. Goggins W., Gao W., and Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer 111 (2004) 792-794
15. Goggins W., Daniels G.H., and Tsao H. Elevation of thyroid cancer risk among cutaneous melanoma survivors. Int J Cancer 118 (2006) 185-188
16. Borg A., Sandberg T., Nilsson K., Johannsson O., Klinker M., Masback A., et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92 (2000) 1260-1266
17. Schenk M., Severson R.K., and Pawlish K.S. The risk of subsequent primary carcinoma of the pancreas in patients with cutaneous malignant melanoma. Cancer 82 (1998) 1672-1676
18. Lynch H.T., and Fusaro R.M. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 6 (1991) 127-131
19. Bhatia S., Estrada-Batres L., Maryon T., Bogue M., and Chu D. Second primary tumors in patients with cutaneous malignant melanoma. Cancer 86 (1999) 2014-2020
20. Swerdlow A.J., Storm H.H., and Sasieni P.D. Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer 61 (1995) 773-779
21. Bergman W., Watson P., de Jong J., Lynch H.T., and Fusaro R.M. Systemic cancer and the FAMMM syndrome. Br J Cancer 61 (1990) 932-936
22. National Cancer Institute. SEER modification of the ICCC. Available from: URL:http://seer.cancer.gov/iccc/seericcc.html. Accessed December 12, 2006.
23. Scelo G., Boffetta P., Autier P., Hemminki K., Pukkala E., Olsen J.H., et al. Associations between ocular melanoma and other primary cancers: an international population-based study. Int J Cancer 120 (2007) 152-159
24. Hanlon F.R. Multiple primary carcinomas. Am J Cancer 15 Suppl (1931) 2001-2012
25. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
26. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., and Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63 (2003) 1454-1457
27. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91 (1999) 1310-1316
28. Whelan A.J., Bartsch D., and Goodfellow P.J. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333 (1995) 975-977
29. Goldstein A.M., Fraser M.C., Struewing J.P., Hussussian C.J., Ranade K., Zametkin D.P., et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333 (1995) 970-974
30. Soufir N., Avril M.F., Chompret A., Demenais F., Bombled J., Spatz A., et al. The French Familial Melanoma Study Group. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France [erratum in Hum Mol Genet 1998;7:941]. Hum Mol Genet 7 (1998) 209-216
31. Oram S.W., Liu X.X., Lee T.L., Chan W.Y., and Lau Y.F. TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells. BMC Cancer 6 (2006) 154
32. Fortes C., and de Vries E. Nonsolar occupational risk factors for cutaneous melanoma. Int J Dermatol 47 (2008) 319-328
33. Desmond R.A., and Soong S.J. Epidemiology of malignant melanoma. Surg Clin North Am 83 (2003) 1-29
34. Nelemans P.J., Verbeek A.L., and Rampen F.H. Nonsolar factors in melanoma risk. Clin Dermatol 10 (1992) 51-63
35. Kelsey J.L., and Horn-Ross P.L. Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 15 (1993) 7-16
36. Rhodes A.R., Weinstock M.A., Fitzpatrick T.B., Mihm Jr. M.C., and Sober A.J. Risk factors for cutaneous melanoma: a practical method of recognizing predisposed individuals. JAMA 258 (1987) 3146-3154
37. Gandini S., Sera F., Cattaruzza M.S., Pasquini P., Picconi O., Boyle P., et al. Meta-analysis of risk factors for cutaneous melanoma, II: sun exposure. Eur J Cancer 41 (2005) 45-60
38. Ortiz C.A., Goodwin J.S., and Freeman J.L. The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma. Med Sci Monit 11 (2005) RA163-RA172
39. Faggiano F., Partanen T., Kogevinas M., and Boffetta P. Socioeconomic differences in cancer incidence and mortality. IARC Sci Publ 138 (1997) 65-176
40. Giovino G.A., Henningfield J.E., Tomar S.L., Escobedo L.G., and Slade J. Epidemiology of tobacco use and dependence. Epidemiol Rev 17 (1995) 48-65
41. Levitz J.S., Bradley T.P., and Golden A.L. Overview of smoking and all cancers. Med Clin North Am 88 (2004) 1655-1675 xiii
42. McKenna D.B., Stockton D., Brewster D.H., and Doherty V.R. Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br J Cancer 88 (2003) 74-78
43. Greenwald P. Lifestyle and medical approaches to cancer prevention. Recent Results Cancer Res 166 (2005) 1-15
44. Allan J.M., and Travis L.B. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 5 (2005) 943-955
45. Atallah E., and Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6 (2005) 185-193
46. Horn-Ross P.L., Ljung B.M., and Morrow M. Environmental factors and the risk of salivary gland cancer. Epidemiology 8 (1997) 414-419
47. Levi F., Randimbison L., La Vecchia C., Erler G., and Te V.C. Incidence of invasive cancers following squamous cell skin cancer. Am J Epidemiol 146 (1997) 734-739
48. Adami J., Frisch M., Yuen J., Glimelius B., and Melbye M. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ 310 (1995) 1491-1495
49. Bentham G. Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales. BMJ 312 (1996) 1128-1131
50. Koh H.K., Geller A., Miller D.R., Clapp R.W., and Lew R.A. Underreporting of cutaneous melanoma in cancer registries nationwide. J Am Acad Dermatol 27 (1992) 1035-1036
51. Merlino L.A., Sullivan K.J., Whitaker D.C., and Lynch C.F. The independent pathology laboratory as a reporting source for cutaneous melanoma incidence in Iowa, 1977-1994. J Am Acad Dermatol 37 (1997) 578-585
52. Cockburn M., Swetter S.M., Peng D., Keegan T.H.M., Deapen D., and Clarke C.A. Melanoma under-reporting: why does it happen, how big is the problem, and how do we fix it?. J Am Acad Dermatol 59 (2008) 1081-1085